2024-10-17 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance Analysis:**

* **Cumulative Return:**  REGN has generated a cumulative return of 93.64% compared to the S&P 500 (VOO) which has returned 135.94%. This puts REGN **42.3% behind the S&P 500**, with a relative divergence of 33.71%. 

**2. Recent Price Action:**

* **Closing Price:** $1016.53
* **5-day Moving Average:** $1011.76
* **20-day Moving Average:** $1046.22
* **60-day Moving Average:** $1107.04

The price is currently below all three moving averages, suggesting potential downward pressure in the short-term.

**3. Technical Indicators:**

* **RSI:** 44.97 (Neutral) - The RSI suggests the stock is neither overbought nor oversold.
* **PPO:** -0.02 (Weak) - The PPO indicates weak momentum and a possible downward trend.
* **Delta_Previous_Relative_Divergence:** -23.89 (Negative) - Indicates a short-term downward trend in relative divergence. 
* **Expected Return:** 0.0% - This suggests a potential 5-year expected return aligned with the S&P 500, offering no significant outperformance over the benchmark.

**4. Recent Earnings and Outlook:**

* **Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

* **Analysis:** The company has shown strong revenue growth in recent quarters, but its most recent EPS result missed analyst expectations. 

**5. News and Recent Developments:**

* **Recent Market Outlook:** The market outlook for REGN is currently mixed. While the company's strong revenue growth and innovative pipeline are positive factors, concerns remain around the company's dependence on a few key drugs and the potential for competition in the market.
* **Analyst Opinions:**  Analyst opinions on REGN vary, with some analysts maintaining a bullish stance due to the company's strong fundamentals and pipeline. Others have expressed concerns about the recent earnings miss and potential competitive pressures.
* **Performance Highlights:** REGN's performance has been impacted by regulatory scrutiny and potential competition, which has weighed on the stock price in recent months. 

**6. Overall Analysis:**

REGN is a promising company with a strong track record of innovation. However, the stock has underperformed the market in recent times, and its recent earnings miss raises concerns about its future prospects. 

**7. Conclusion:**

REGN currently appears to be in a period of uncertainty with some investors showing concerns while others remain hopeful about its future. The stock's underperformance relative to the broader market and its mixed performance on technical indicators suggest caution in the short term.  Investors should closely monitor the company's future earnings reports and any potential regulatory updates to gauge its long-term trajectory.
